GLP-1s and Reproductive Health: What OB-GYN Patients Should Know

*This article is for education only and does not constitute medical advice. It is not a substitute for professional evaluation by a licensed clinician. Always consult a qualified healthcare provider before starting, stopping, or changing any GLP-1 therapy, contraceptive method, or reproductive health plan. GLP-1 receptor agonists are not approved for use during pregnancy. If you are planning to conceive, or if you think you may be pregnant, contact your prescriber immediately.*

---

If you are managing PCOS, thinking about fertility, navigating perimenopause, or trying to understand whether a GLP-1 medication belongs in your reproductive health conversation — you are not alone. OB-GYNs across the country are fielding more questions about semaglutide, tirzepatide, and related medications than ever before.

A 2026 narrative review in *Cureus*, written specifically for obstetrician-gynecologists, consolidated what is known about GLP-1 receptor agonists across the full reproductive spectrum — contraception, preconception planning, PCOS, pregnancy safety, postpartum use, and lactation.[^1] Its central message is one patients should hear too: GLP-1 medications may offer reproductive-relevant benefits for some patients with metabolic dysfunction, but pregnancy and lactation data remain limited. Counseling should be individualized, agent-specific, and centered on your pregnancy intentions, contraceptive reliability, and metabolic risk.

This post translates that clinical review into a patient-facing guide. The goal is to help you walk into your next OB-GYN appointment informed and ready to ask the right questions.

---

Why OB-GYNs Are Fielding More GLP-1 Questions Than Ever

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda), and dual GIP/GLP-1 agents — have moved well beyond endocrinology clinics. They are now prescribed widely for weight management, insulin resistance, and metabolic syndrome, meaning a growing share of reproductive-aged patients are taking one, considering one, or recently discontinued one.

The questions follow predictably: Can this medication affect my fertility? Should I stop before trying to conceive? Does it interact with my birth control? Can it help my PCOS? Is it safe during pregnancy or breastfeeding? The *Cureus* review addresses all of these, and the answers are more nuanced than social media suggests.[^1]

---

PCOS and Metabolic Correction: The Insulin-Resistance Overlap

Polycystic ovary syndrome affects an estimated 6–12% of reproductive-aged women. Its root physiology is not purely ovarian — it is deeply metabolic. Insulin resistance is present in 70–80% of women with PCOS, and it drives hyperandrogenism, disrupted ovulation, and weight gain that further worsens insulin signaling. The cycle is self-reinforcing.

This is where GLP-1 medications enter the conversation. By improving insulin sensitivity and supporting weight loss, GLP-1 receptor agonists may address the metabolic root of PCOS rather than just its symptoms. The *Cureus* review notes that available evidence suggests potential reproductive benefits in some patients with metabolic dysfunction or PCOS, particularly those who are overweight.[^1]

A registered clinical trial is directly testing this: GLP-1 agonists versus oral contraceptives for reproductive and cardiovascular outcomes in overweight PCOS.[^2] The trial is significant because it challenges the current default of using oral contraceptives for cycle regulation — an approach that can regulate bleeding patterns but may exacerbate underlying metabolic dysfunction. If GLP-1 therapy can address hyperandrogenism and cardiometabolic risk simultaneously, it would shift PCOS management toward treating it as a metabolic-reproductive disorder.

GLP-1 medications are not approved as a PCOS treatment, and no one should start one expecting it to "fix" PCOS or restore ovulatory function on a predictable timeline. But for women with PCOS who also have obesity or insulin resistance, the metabolic correction these medications provide may have downstream reproductive effects worth discussing with their care team.

For a deeper look at the metabolic foundations, our guide to insulin resistance and metabolic health covers the mechanisms connecting metabolic dysfunction to hormonal outcomes.

---

Fertility Outcomes: Weight Management and Ovulatory Function

The relationship between body weight and fertility is well established. Obesity is associated with anovulation, irregular cycles, reduced response to fertility treatments, and higher miscarriage rates. Weight loss of even 5–10% can restore spontaneous ovulation in some women with obesity-related infertility.

GLP-1 medications are among the most effective pharmacological tools for achieving clinically meaningful weight loss. The logical question: if GLP-1 therapy helps you lose weight, and weight loss improves ovulatory function, does GLP-1 therapy improve fertility?

The indirect evidence supports the connection, but direct fertility-specific trials are limited. The *Cureus* review highlights that the mechanisms by which GLP-1 receptor agonists affect ovulation — through weight reduction, improved insulin sensitivity, and potential direct effects on ovarian GLP-1 receptors — are biologically plausible but not yet fully characterized in human studies.[^1]

What we know: weight loss through GLP-1 therapy can improve menstrual cyclicity in women with obesity and PCOS; improved insulin sensitivity may lower ovarian androgen production and support follicular development; observational studies report improved ovulation rates in PCOS patients treated with GLP-1 agonists alongside lifestyle intervention.

What we do not know: whether GLP-1 medications improve fertility independent of weight loss; whether they affect oocyte quality, implantation, or early pregnancy outcomes; whether different agents have meaningfully different reproductive effects.

If you are pursuing fertility and on a GLP-1, the conversation with your reproductive endocrinologist should happen early — ideally before you begin actively trying to conceive.

---

Contraception and Preconception Planning: When to Discontinue

This section matters most for anyone of reproductive age on a GLP-1.

GLP-1 receptor agonists are not approved for use during pregnancy. Animal studies have shown adverse effects, including skeletal and cardiac abnormalities, at clinically relevant doses. Human pregnancy data are limited to inadvertent exposures — too sparse to establish safety. The *Cureus* review is explicit: until stronger prospective data exist, GLP-1 therapy during pregnancy should be avoided, and counseling should center on pregnancy intention and contraceptive reliability.[^1]

Contraceptive considerations

GLP-1 receptor agonists slow gastric emptying — one of their primary mechanisms for reducing appetite and glucose spikes. But delayed gastric emptying can theoretically alter absorption of oral medications, including combined oral contraceptives. The *Cureus* review flags pharmacokinetic interactions with oral hormonal contraceptives as a specific counseling point.[^1]

This does not mean oral contraceptives stop working on a GLP-1. It means the reliability margin may shift, particularly during dose escalation or periods of significant gastrointestinal side effects. Patients relying on oral contraceptives should discuss whether backup methods are appropriate. Non-oral options — IUD, implant, patch, ring — sidestep this concern entirely.

Preconception washout

For patients planning to conceive, the general guidance is to discontinue GLP-1 therapy before attempting pregnancy. Because these medications have long half-lives — semaglutide's is approximately one week — a washout period is necessary to ensure clearance before conception. The specific duration depends on the agent and should be determined by your prescriber with your OB-GYN. The key principle: discontinuation should be planned, not reactive.[^1]

Inadvertent early-pregnancy exposure

Given long half-lives and the reality that pregnancies are not always planned, inadvertent exposure occurs. The *Cureus* review provides guidance on management: contact your clinician immediately, discontinue the medication, and undergo individualized risk assessment.[^1] If you discover you are pregnant while on a GLP-1, do not wait for your next appointment — call your prescriber the same day.

---

Perimenopausal and Menopausal Metabolic Shift

There is a reproductive health audience chronically underserved in GLP-1 conversations: perimenopausal and menopausal women.

Estrogen decline triggers a cascade of metabolic changes: visceral fat redistribution (fat shifts from hips to abdomen), increased insulin resistance, unfavorable lipid changes, and rising cardiovascular risk. Many women find that the eating and exercise routines that maintained their weight for years suddenly stop working. They are not imagining this — the metabolic environment has genuinely shifted.

GLP-1 medications may address this directly. By improving insulin sensitivity, supporting visceral fat reduction, and providing cardiometabolic benefits, they align with the specific metabolic challenges of menopause. The *Cureus* review notes this peri-menopausal angle is underexplored in the GLP-1 reproductive health literature, but mechanistically the fit is strong.[^1]

This connects to our broader coverage of testosterone in women's health and hormone-metabolism connections.

---

Postpartum Use and Lactation

The *Cureus* review also addresses postpartum prescribing and breastfeeding.[^1] Postpartum GLP-1 use may be relevant for women who were on a GLP-1 before pregnancy, gained weight during pregnancy, or developed gestational diabetes.

However, there are no data on GLP-1 receptor agonists in human breast milk, and no established safety data for infants exposed through breastfeeding. GLP-1 medications are generally not recommended during lactation. Patients who wish to breastfeed and want to resume GLP-1 therapy face a decision that should involve their OB-GYN, pediatrician, and prescriber together.

For patients who are not breastfeeding, the postpartum period can be a strategic window for metabolic re-optimization — but the decision should account for recovery, nutritional status, mental health, and future pregnancy plans.

---

What to Ask Your OB-GYN

✦Given my metabolic risk factors and reproductive goals, is a GLP-1 appropriate for me?
✦If I am planning to conceive, when should I discontinue, and what washout period applies to my medication?
✦Am I using the most reliable contraceptive method while on this medication?
✦If I have PCOS, could a GLP-1 address the metabolic root alongside or instead of oral contraceptives?
✦I am in perimenopause — could a GLP-1 be part of my metabolic health strategy?
✦If I become pregnant unexpectedly, what should I do immediately?

---

FAQ

Can GLP-1 medications affect my fertility?

Indirectly, yes — through weight loss and improved insulin sensitivity, GLP-1 therapy may improve ovulatory function, particularly in women with obesity or PCOS. However, there are no large fertility-specific randomized trials confirming direct fertility improvement. The reproductive benefits observed so far are primarily secondary to metabolic improvement. If you are experiencing infertility and on or considering a GLP-1, discuss timing and goals with your reproductive endocrinologist.

Should I stop my GLP-1 before trying to conceive?

Yes. GLP-1 receptor agonists are not approved during pregnancy, and animal studies have shown reproductive risks. Because these medications have long half-lives, they must be discontinued with a planned washout period before conception. The specific timing depends on your medication and should be set by your prescriber with your OB-GYN. Do not stop abruptly without a plan — talk to your clinician about when and how to discontinue based on your pregnancy timeline.

Can GLP-1s help with PCOS symptoms?

Evidence suggests potential benefits. GLP-1 medications improve insulin sensitivity and support weight loss, both of which address the metabolic root of PCOS. Some studies report improved menstrual cyclicity and ovulation in overweight PCOS patients. A clinical trial is currently comparing GLP-1 agonists directly against oral contraceptives for reproductive and cardiovascular outcomes in overweight PCOS.[^2] However, GLP-1s are not approved as a PCOS treatment, and the evidence is still emerging. Discuss with your endocrinologist or OB-GYN.

Do GLP-1s interact with birth control?

GLP-1 medications slow gastric emptying, which can theoretically alter absorption of oral contraceptives. The *Cureus* review flags this as a specific counseling point.[^1] This does not mean oral contraceptives stop working, but if you experience significant gastrointestinal side effects — especially vomiting — backup contraception may be advisable. A non-oral method (IUD, implant, patch, ring) sidesteps this concern entirely.

Are GLP-1s safe during perimenopause or menopause?

GLP-1 medications are not contraindicated during perimenopause or menopause. The metabolic benefits — improved insulin sensitivity, visceral fat reduction, cardiometabolic risk reduction — align well with the metabolic challenges of the menopausal transition. Estrogen decline increases insulin resistance and promotes abdominal fat, and GLP-1 therapy may help counteract these shifts. The decision should be individualized based on your full metabolic and cardiovascular profile.

---

The Bottom Line

GLP-1 medications are rewriting metabolic medicine, and their intersection with reproductive health is real and evolving.

For women with PCOS, the metabolic correction GLP-1 therapy provides may address root physiology in ways oral contraceptives alone cannot. For those planning pregnancy, the discontinuation timeline is non-negotiable — these medications are not approved during pregnancy, and the washout period requires planning. For perimenopausal and menopausal women, GLP-1s offer a metabolic tool that matches the specific challenges of estrogen decline. And for every patient of reproductive age on a GLP-1, contraceptive reliability and pregnancy intention should be active parts of the prescribing conversation.

The *Cureus* review frames it well: counseling should be individualized, agent-specific, and centered on shared decision-making.[^1] The conversation between you and your OB-GYN is where the real answers live — informed by evidence and shaped by your specific health profile.

---

*If you are exploring GLP-1 therapy for metabolic health, PCOS management, or the metabolic challenges of perimenopause, consult with a qualified healthcare provider in the Dallas–Fort Worth area who can evaluate your individual health profile, reproductive goals, and metabolic risk factors.*

---

[^1]: Almaradweh S, Mousa E. "Glucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists." *Cureus*, 2026 Jul;18(7):e111915. PMID: 42544159. Narrative review synthesizing evidence on GLP-1 RA use across the reproductive spectrum, including PCOS, ovulation, contraception, pregnancy planning, discontinuation, postpartum use, and lactation.

[^2]: ClinicalTrials.gov. "The Effect of GLP-1 Agonists Versus Oral Contraceptives on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS." Registered trial comparing GLP-1 agonists vs. oral contraceptives for metabolic-reproductive outcomes in overweight women with PCOS. Results not yet published as of mid-2026.